Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of abatacept, rituximab, or anti-TNF alpha therapy in rheumatoid arthritis after anti-TNF failure
NL-OMON32522Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of abatacept and rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: DAS28 at 12 months, Quality-adjusted life years and 1 more. Planned start Jan 2009; status: not yet recruiting.
02
Drugs
abataceptrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON32522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32522.